Research Advances in the Use of Histone Deacetylase Inhibitors for Epigenetic Targeting of Cancer

(E-pub Ahead of Print)

Author(s): Yu Bai, Daid Ahmad, Ting Wang*, Guihua Cui, Wenliang Li*.

Journal Name: Current Topics in Medicinal Chemistry

Become EABM
Become Reviewer


The causes and progression of cancer are controlled by epigenetic processes. The mechanisms involved in epigenetic regulation of cancer development, gene expression, and signaling pathways have been studied. Histone deacetylases (HDACs) have a major impact on chromatin remodeling and epigenetics, making their inhibitors a very interesting area of cancer research. This review comprehensively summarizes the literature regarding HDAC inhibitors (HDACis) as an anticancer treatment published in the past few years. In addition, we explain the mechanisms of their therapeutic effects on cancer. An analysis of the beneficial characteristics and drawbacks of HDACis also is presented, which will assist preclinical and clinical researchers in the design of future experiments to improve the therapeutic efficacy of these drugs and circumvent the challenges in the path of successful epigenetic therapy. Future therapeutic strategies may include a combination of HDACis and chemotherapy or other inhibitors to target multiple oncogenic signaling pathways.

Keywords: Histone deacetylase (HDAC) inhibitors, cancer, mechanisms, histone deacetylases, epigenetic therapy, signaling pathways.

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1568026619666190125145110
Price: $95

Article Metrics

PDF: 6